193 related articles for article (PubMed ID: 33782049)
1. Randomized Controlled Trial of the Gastrin/CCK
Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
[TBL] [Abstract][Full Text] [Related]
2. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
3. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
4. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
5. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
8. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.
Lee Y; Urbanska AM; Hayakawa Y; Wang H; Au AS; Luna AM; Chang W; Jin G; Bhagat G; Abrams JA; Friedman RA; Varro A; Wang KK; Boyce M; Rustgi AK; Sepulveda AR; Quante M; Wang TC
Oncotarget; 2017 Jan; 8(1):203-214. PubMed ID: 27448962
[TBL] [Abstract][Full Text] [Related]
9. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.
Haigh CR; Attwood SE; Thompson DG; Jankowski JA; Kirton CM; Pritchard DM; Varro A; Dimaline R
Gastroenterology; 2003 Mar; 124(3):615-25. PubMed ID: 12612900
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.
Wang JS; Varro A; Lightdale CJ; Lertkowit N; Slack KN; Fingerhood ML; Tsai WY; Wang TC; Abrams JA
Am J Gastroenterol; 2010 May; 105(5):1039-45. PubMed ID: 19904251
[TBL] [Abstract][Full Text] [Related]
12. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
13. Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.
Peter S; Pendergraft A; VanDerPol W; Wilcox CM; Kyanam Kabir Baig KR; Morrow C; Izard J; Mannon PJ
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00199. PubMed ID: 32955191
[TBL] [Abstract][Full Text] [Related]
14. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
[TBL] [Abstract][Full Text] [Related]
15. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
16. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
17. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
18. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
[TBL] [Abstract][Full Text] [Related]
19. Secretory Phospholipase A
Gergen AK; Jarrett MJ; Li A; White AM; Meng X; Fullerton DA; Weyant MJ
J Surg Res; 2021 Mar; 259():562-568. PubMed ID: 33261858
[TBL] [Abstract][Full Text] [Related]
20. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
